Related Experiment Videos
Selective agonists of tachykinin binding sites
S Lavielle1, G Chassaing, D Loeuillet
1Laboratoire de Chimie Organique Biologique, CNRS UA 493, Paris, France.
Fundamental & Clinical Pharmacology
|January 1, 1990
Summary
Researchers designed selective agonists for mammalian tachykinin binding sites, including Substance P (SP) at NK-1, Neurokinin A (NKA) at NK-2, and Neurokinin B (NKB) at NK-3 receptors.
Area of Science:
- Neuroscience
- Pharmacology
- Biochemistry
Background:
- Mammalian tachykinins like Substance P (SP), Neurokinin A (NKA), and Neurokinin B (NKB) interact with distinct binding sites.
- These binding sites, classified as NK-1, NK-2, and NK-3 subclasses, are present in both central and peripheral nervous systems.
- SP preferentially binds to NK-1, while NKA and NKB show selectivity for NK-2 and NK-3, respectively.
Purpose of the Study:
- To design selective agonists for the NK-1, NK-2, and NK-3 binding sites.
- To utilize complementary strategies for drug design and discovery.
Main Methods:
- 3-dimensional structure analysis using Nuclear Magnetic Resonance (NMR) spectroscopy.
- Structure-activity relationship (SAR) studies.
- Chemical synthesis of novel peptide analogues.
Main Results:
- Selective NK-1 agonists developed include [Pro9] SP, [Pro10] SP, and cyclic analogues like [Cys3,6, Tyr8, Pro9] SP.
- [Lys5] NKA(4-10) was identified as a potent, water-soluble NK-2 agonist.
- A water-soluble NK-3 selective agonist, [Pro7] NKB, was synthesized, demonstrating discrimination between NK-2 and NK-3 sites.
Conclusions:
- The study successfully designed and identified selective agonists for mammalian tachykinin receptor subtypes.
- These findings contribute to the understanding of tachykinin receptor pharmacology and offer potential therapeutic agents.